OEOlga I. Evsyukova

Olga I. Evsyukova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Olga I. Evsyukova has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Safety and toxicity of cabozantinib monotherapy in patients with advanced renal cell carcinoma: a Russian multicenter observational study

    by Maria I. Volkova, Alexey S. Kalpinskiy, Konstantin V. Menshikov, Lilia V. Gorbuleva, Alexander V. Sultanbaev, Olga I. Evsyukova, Varazdat R. Meltonian, Sergey V. Mishugin, Mikhail R. Maturov, Anna S. Olshanskaya, et al.

    Aim. To assess the safety and to analyze an influence of cabozantinib monotherapy toxicity on treatment efficacy in unselected Russian patients with metastatic renal cell carcinoma (mRCC). Materials and methods. Medical data of 92 patients with verified mRCC were included in the study. The median age of the patients was 56 (1979) years, most of them - 60 (65.2%) were of male gender. Twenty five (27.2%) persons had Eastern Cooperative Oncology Group performance status (ECOG PS). At the time of cabozantinib monotherapy start 5 (5.4%) patients had favorable, 54 (58.7%) intermediate, and 33 (35.9%) unfavorable prognosis by International Metastatic Renal Cancer Database Consortium (IMDC) model. Eighty-three (90.2%) patients were pretreated, including 76 (82.6%) patients who previously received anti-angiogenic agents. All patients were administered with cabozantinib monotherapy (60 mg/day); dose adjustment was performed according to the instruction. Results. Adverse events (AEs) were reported in 81 (88.0%) of 92 patients; 30 (32.6%) AEs were grade 34. Toxicity-related dose reduction of cabozantinib was required in 28 (30.4%), treatment interruption in 15 (16.3%), and discontinuation in 2 (2.2%) patients. The most common AEs were hypertension (69 patients, 75.0%), asthenia (47 patients, 51.1%), diarrhea (43 patients, 46.7%), and palmar-plantar erythrodysesthesia (43 patients, 46.7%). The most common severe AEs were: arterial hypertension (17 patients, 18.5%), diarrhea (6 patients, 6.5%), and palmar-plantar erythrodysesthesia (2 patients, 2.2%). The most frequent laboratory abnormalities during therapy were elevated serum transaminases (33 patients, 35.9%), anemia (13 patients, 14.1%), and thrombocytopenia (10 patients, 10.9%). No previously unreported AEs or laboratory abnormalities were observed. There was a significant increase in progression-free survival (hazard ratio 2.5; 95% confidence interval 1.05.9; p=0.046) and overall survival (hazard ratio 3.0; 95% confidence interval 1.28.3; p0.025) in patients with treatment-related arterial hypertension. Conclusion. The observational study confirmed the acceptable safety profile of cabozantinib in the first and subsequent lines of treatment in mRCC patients. No new safety signals were identified. Treatment-related arterial hypertension may be a favorable predictor of survival.


  • Open Access

    Efficacy and safety of cabozantinib in metastatic renal cell carcinoma patients: Russian multicenter observational study

    by M. I. Volkova, A. S. Kalpinskiy, K. V. Men'SHikov, L. V. Gorbuleva, O. I. Evsyukova, V. R. Meltonyan, S. V. Mishugin, M. R. Maturov, A. S. Ol'SHanskaya, D. Yu. Shemetov, et al.

    Purpose: an assessment of efficacy and safety of cabozantinib in unselected patients with metastatic renal cell carcinoma in the first and subsequent lines of therapy.Materials and methods. Russian multicenter observational study included 92 consecutive patients with morphologically verified metastatic renal cell carcinoma treated with cabozantinib (60 mg/d) in 16 Russian centers. Median age of the patients was 56 (19-79) years, a male-to-female ratio - 3:1. At the start of cabozantinib therapy 27.2 % of patients had ECOG PS 2. Most common histological type of kidney cancer was clear-cell RCC (90.2 %). Most patients were diagnosed with synchronous (71.7 %) multiple metastases (60.9 %). Previous nephrectomy was performed in 87.0 % of cases. Prognosis according to International Metastatic Renal Cancer Database Consortium (IMDC) score was assessed as favorable in 5.4 %, intermediate - in 58.7 % and poor - in 35.9 % patients. Cabozantinib as the first-line therapy was administered in 9 (9.8 %), following 1-5 lines of systemic treatment - in 83 (90.2 %) cases. Median follow-up was 11 (2.3-44.5) months.Results. In patients, receiving cabozantinib as the first-line therapy, objective response rate was 66.7 %, tumor control was reached in 100 % of cases. Median time to the objective response was 2.6 (1.9-3.6) months, median objective response duration - 13.2 (6.2-21.5) months. Median progression-free survival (PFS) and overall survival (OS) were not reached, 6- and 12-months PFS was 77.8 % and 77.8 %, 6- and 12-months OS - 88.9 % and 88.9 % respectively. Cabozantinib as the second and subsequent lines of therapy provided objective response rate of 34.9 %, tumor control rate - 97.6 %. Median time to the objective response was 2.5 (1.8-4.1) months, median objective response duration - 12.6 (5.5-27.3) months. Median PFS was not reached (6- and 12-months PFS - 92.5 % and 73.1 % respectively), median OS was 32.6 months (6- and 12-months OS - 97.4 % and 80.8 % respectively). Any adverse events (AE) developed in 88.8 %, AE grade III-IV - in 32.6 % of cases. Most frequent AE grade III-IV included arterial hypertension (18.5 %), diarrhea (6.5 %) and palmar-plantar erythrodysesthesia (6.5 %). Unacceptable toxicity demanded treatment cancellation in 2.2 %, therapy interruption - in 16.3 % and dose reduction - in 30.4 % of patients.Conclusion. Cabozantinib as the first and subsequent lines of therapy for metastatic renal cell carcinoma patients in the real world practice demonstrated high efficacy and better tolerability comparing with population assigned for cabozantinib monotherapy in the randomized phase II-III trials.


  • Open Access

    Efficacy and safety of lenvatinib and everolimus combination in patients with metastatic renal cell carcinoma progression following targeted antiangiogenic therapy: secondary analysis of data obtained in the Russian multicenter observational study

    by M. I. Volkova, A. S. Kalpinskiy, P. S. Borisov, O. I. Evsyukova, A. S. Olshanskaya, V. B. Matveev, B. Ya. Alekseev, E. V. Peganova, A. F. Nasretdinov, Е. В. Лымарь, et al.

    Objective. The primary endpoint was progression-free survival; secondary endpoints included overall survival, objective response rate and duration, tumor control rate and duration, as well as safety profile of lenvatinib with everolimus in consecutive patients with advanced renal cell carcinoma who had disease progression after targeted antiangiogenic therapy.Materials and methods. This observational study included 129 consecutive patients with metastatic renal cell carcinoma resistant to targeted antiangiogenic therapy. The median age was 60 years; a male to female ratio was 3.1:1. Twenty-seven patients (20.9 %) had ECOG performance status of 2—4. The majority of study participants (n = 127; 98.4 %) had multiple metastases. Tumor lesions were located in 1 organ in 104 cases (80.6 %). The primary tumor was removed in 110 (85.3 %), including 39 (30.2 %) patients undergone cytoreductive surgery. Seventy patients (54.2 %) had earlier received more than one line of therapy. Upon enrollment, there were 13 IMDC favourable-risk patients (10.1 %), 86 IMDC intermediate-risk patients (66.6 %), and 29 IMDC poor-risk patients (22.5 %). In one patient (0.8 %), the IMDC risk was not estimated. All patients received lenvatinib at a dose of 18 mg/day and everolimus at a dose of 5 mg/day. The median follow-up was 10.5 (1—30) months.Results. Median progression-free survival was 14.9 (11.9—17.9) months; overall survival was 19.9 (15.2—24.6) months. The objective response rate was 17.0 % (median duration 9.7 (2.8—16.5) months); tumor control rate was 72.9 % (median duration 10.0 (2.5—17.5) months). Adverse events were observed in 112patients (86.8 %) with grade III—IVadverse events registered in 27participants (20.9 %). Five participants (3.9 %) needed inpatient treatment of adverse events; one patient (0.8 %) died due to adverse events. Adverse events required treatment discontinuation in 4 patients (3.1 %), treatment interruption in 35 patients (27.1 %), and dose reduction in 33 patients (25.6 %).Conclusion. The results of the secondary analysis in the ROSLERCM observational study confirmed the results obtained earlier on the efficacy and safety of the lenvatinib plus everolimus combination in the second- and subsequent-line therapy for advanced renal cell carcinoma resistant to targeted antiangiogenic therapy in consecutive Russian patients.


  • Open Access

    International experience of using olaparib for metastatic castration-resistant prostate cancer: literature review

    by V. B. Matveev, O. A. Khalmurzaev, O. I. Evsyukova

    The following review presents a problem of metastatic castration-resistant prostate cancer and its association with germline or somatic mutations in homologous recombination repair (HRR). In 2020, olaparib was approved in the Russian Federation as a monotherapy for metastatic castration-resistant prostate cancer with germline or somatic mutations of genes involved in DNA repair by homologous recombination, after progression on therapy with new hormonal drugs. We describe a review of the main olaparib clinical trials assessing its efficacy, safety and tolerance in metastatic castration-resistant prostate cancer patients.


  • Open Access

    Renal cell carcinoma: what’s new in 2019

    by О. I. Evsyukova, V. В. Matveev

    This review of renal cell carcinoma describes new diagnostics and treatment standards, new guidelines from international professional organizations and key studies, published in 2019.


  • Open Access

    Efficacy and safety of lenvatinib in combination with everolimus in metastatic renal cell carcinoma resistant to antiangiogenic targeted therapy: Russian multicenter observational study ROSLERCM

    by M. I. Volkova, А. М. Абдельгафур, M. T. Aivazov, Z. V. Amoev, K. G. Babina, P. S. Borisov, A. A. Vorontsovа, I. V. Evstigneeva, O. I. Evsyukova, O. V. Zhelezin, et al.

    Objective: an assessment of efficacy and safety of lenvatinib in combination with everolimus in unselected patients with metastatic renal cell carcinoma (mRCC) progressed during or following ≥1 line of antiangiogenic targeted therapy.Material. Russian multicenter observational study ROSLERCM included 73 consecutive patients with morphologically verified mRCC progressed during or following ≥1 line of antiangiogenic targeted therapy, treated with lenvatinib (18 mg/d) and everolimus (5 mg/d) in 20 Russian centers. Median age of the patients was 59 (23–73) years, a male-to-female ratio – 3:1. Most common histological type of kidney cancer was clear-cell RCC (71 (95.8 %)). More than 2 lines of previous therapy were administered in 45 (61.6 %) cases. Most patients were diagnosed with multiple metastases (71 (97.3 %)) in 1 site (61 (83.6 %)). Nephrectomy was performed in 87.7 % (64/73) of cases. At the combined therapy start ECOG PS 2–4 was registered in 16 (20.5 %), poor prognosis according to IMDC score – in 33 (45.2 %) patients. Median follow-up was 9.7 (1–26) months.Results. Median progression-free survival achieved 16.9 (95 % confidence intervals (CI) 12.1–20.6), overall survival – 20.8 (95 % CI 15.7–25.9) months. Objective response rate was 11 % (8/73); tumor control was reached in 93.2 % (68/73) of cases. Median objective response duration was 10.5 (4.3–16.8) months, tumor control duration – 10.0 (2.5–17.5) months. Any adverse events developed in 83.6 % (61/73), adverse events grade III–V – in 23.3 % (17/73) of cases. Most frequent AE grade III–IV were diarrhea (10 (13.6 %)) and arterial hypertension (6 (8.2 %)). Unacceptable toxicity demanded treatment cancellation in 4.2 % (3/73), therapy interruption – in 30.1 % (22/73) and dose reduction – in 32.9 % (24/73) of patients.Conclusion. Unselected mRCC patients administered with combined targeted therapy in the real world practice were registered with similar survival, lower objective response rate, and better tolerability comparing with population assigned for lenvatinib plus everolimus in the randomized phase II trial.


  • Open Access

    Lenvatinib in combination with everolimus in metastatic renal cell carcinoma resistant to antiangiogenic targeted therapy: an initial Russian experience

    by M. I. Volkova, O. I. Evsyukova, A. S. Olshanskaya, V. B. Matveev

    Objective: a preliminary assessment of safety, tolerability, and efficacy of lenvatinib in combination with everolimus in unselected patients with metastatic renal cell carcinoma (mRCC) resistant to antiangiogenic targeted therapy.Materials and methods. We analyzed medical data of 19 consecutive mRCC patients received lenvatinib in combination with everolimus following antiangiogenic targeted therapy failure. Median age was 55 (23–73) years. ECOG PS 0–1 was in 11 (57.9 %), ECOG 2–4 – in 8 (42.1 %) cases. Four (21.1 %) patients were distributed into the good, 10 (52.6 %) – into the intermediate, and 5 (26.3 %) – into the poor IMDC (International Metastatic Renal Cancer Database Consortium) prognostic group. Multiple metastases were diagnosed in 18 (94.7 %), multiple metastatic sites – in 17 (89.5 %), liver metastases – in 6 (37.6 %) cases. All the patients were previously treated with 1–4 lines of therapy (≥2 – 12 (63.1 %)). Median follow-up was 5 (2–10) months.Results. By the time of the analysis 12 (63.2 %) patients are being treated, 7 (36.8 %) – completed combined treatment (due to RCC progression – 4 (21.1 %), toxicity – 2 (10.5 %), death from unrelated reason – 1 (5.3 %)). Median time of completed therapy was not reached, mean treatment time was 5.1 (1.9–11.2) months. Adverse events were registered in 17 (89.5 %) patients (grade III – 3 (15.8 %), grade IV – 0, grade V – 1 (5.3 %)). The most common adverse events were diarrhea (68.4 %), stomatitis (57.9 %), hypertension (42.1 %), and weight loss (47.4 %). Lenvatinib or everolimus dose reduction was demanded in 5 (26.3 %) and 0, therapy interruption – in 5 (26.3 %) and 1 (5.3 %) patient respectively. Maximal response was assessed as partial in 1 (5.3 %) and stabilization – in 18 (94.7 %) cases. Decline of metastases size was registered in 12 (63.2 %) (median – 17 % (3–40 %)), stabilization – in 8 (42.1 %), enlargement – in 1 (5.3 %) patient. Median time to maximal response was 2 (2–4) months. Five-months overall and progression-free survival rates were 76.1 and 87.4 % respectively. Following 2 cycles of combined therapy ECOG PS improved in 11 (57.9 %), stabilized – in 6 (31.6 %), worsened – in 2 (10.5 %) patients.Conclusion. Our preliminary data have confirmed antitumor activity and showed acceptable tolerability of lenvatinib in combination with everolimus in unselected patients with mRCC resistant to antiangiogenic targeted therapy.


  • Open Access

    Evaluation of safety and advisability of salvage lymph node dissection in patients with lymphogenic metastases of prostate cancer after radical treatment

    by O. I. Evsukova, V. A. Chernyaev, O. A. Khalmurzaev, K. A. Khafizov, A. V. Khachaturyan, M. M. Tkhakokhov, V. B. Matveev

    Background. The rate of prostate cancer progression after radical treatment is about 40 %. Currently, some data suggest that patients with oligometastases have a more favorable prognosis than patients with extensive tumor lesions. In 78 % of cases, oligometastases are localized in the pelvic and retroperitoneal lymph nodes. Surgical removal of all detectable metastases can cure prostate cancer recurrence, however the possibility of using salvage lymph node dissection (sLND) in clinical practice remains limited due to the lack of data on surgical and oncological outcomes of this treatment method.The study objective is to evaluate surgical and early oncological outcomes of sLND in patients with progressive prostate cancer after radical treatment.Materials and methods. The study was conducted at the N.N. Blokhin National Medical Research Center of Oncology. The analysis included 17 patients with biochemical prostate cancer recurrence and symptoms of lymphogenic disease progression based on positron emission tomography/computed tomography with radiopharmaceuticals 18F-choline (n = 14; 82.35 %) and 68Ga-prostate-specific membrane antigen (n = 1; 5.88 %) and magnetic resonance lymphography with Combidex (ultra-small superparamagnetic iron oxides, USPIO) (n = 2; 12.0 %). All patients underwent sLND in the period from October of 2014 to December of 2016.Results. Postoperative complications were observed in 58.8 % (n = 10) of cases. No grade III and IV complications per the Clavien–Dindo classification were registered. For median follow up duration of 17.5 (5–31) months, full biochemical response in the form of decreased prostate-specific antigen 0.2 ng/ml was observed in 5 (29.4 %) patients. Mean time to prescription of hormone therapy was 6.6 (1–12) months. Considering this follow up duration, 53 % of patients hadn’t received hormone therapy.Conclusion. Therefore, sLND is a safe surgical intervention with low number of severe complications. sLND can be successfully used in wellselected patients as a diagnostic tool and provide accurate information on the state of lymph nodes. Removal of oligometastases allows to achieve long-term relapse-free period in individual patients and postpone prescription of hormone therapy.